Effects of antifibrinolytic agents on the life span of fibrin sealant☆
References (24)
Fibrin seal: The state of the art
J. Oral Maxillofac. Surg.
(1985)- et al.
Current status of surgical adhesives
J. Surg. Res.
(1990) - et al.
Fibrinolytic potential
- et al.
Studies on the mechanism of the antifibrinolytic action of tranexamic acid
Biochim. Biophys. Acta
(1981) - et al.
Thermodynamic properties of the binding of α-, ω-amino acids to the isolated kringle 4 region of human plasminogen as determined by high sensitivity titration colorimetry
J. Biol. Chem.
(1990) - et al.
Some properties of the antifibrinolytically active isomer of amino-methylcyclohexane caroboxylic acid
Lancet
(1964) - et al.
Structural changes in fibrin clot associated with the proteolytic activity induced by tissue plasminogen activator
- et al.
Aprotinin inhibits urokinase, but not tissue-type plasminogen activator
Thromb. Res.
(1988) Fibrin sealing: Physiologic and biochemical background
Fac. Plast. Surg.
(1985)- et al.
Fibrin glue: The perfect operative sealant
Transfusion
(1990)
Neurosurgical applications of fibrin glue: Augmentation of dural closure in 134 patients
Neurosurgery
Evaluation of dural closure techniques
Cited by (59)
A hybrid scaffold of gelatin glycosaminoglycan matrix and fibrin as a carrier of human corneal fibroblast cells
2021, Materials Science and Engineering CCitation Excerpt :Altering the concentration of key components, including fibrinogen, thrombin, and FXIII, leads to a change in the properties of fibrin scaffolds such as fibrin gelation time, mechanical properties, microstructure and durability [62,63]. However, the notable disadvantage of fibrin scaffolds is their rapid degradation which can be easily delayed by incorporating protease inhibitor agents [60,64–66]. Although fibrin has a wide variety of advantages, it does not meet the requirements for a regenerative matrix on its own due to the fast degradation rate and weak mechanical properties [67–69].
Fibrin matrices: The versatile therapeutic delivery systems
2015, International Journal of Biological MacromoleculesCitation Excerpt :The first commercial, multi donor fibrin-sealant products were made available in Europe in the late 1970s, while Tisseel® was approved in the USA as late as 1998 and distributed for the first time by the Baxter Healthcare Corporation (Glendale, CA). The fibrin sealants currently available commercially (Table 2), are standardized freeze-dried products, rich in clotable fibrinogen, factor FXIII and usually stabilized by anti-fibrinolytic agent like aprotinin [22,23]. Some of the commercial sealants are also being investigated currently for their potential in drug delivery.
Fibrin sealant significantly decrease postoperative drainage in breast reconstruction by deep inferior epigastric perforator (DIEP) flap
2012, Annales de Chirurgie Plastique EsthetiqueFibrin glue as a drug delivery system
2010, Journal of Controlled ReleaseCitation Excerpt :Most formulations of fibrin glue include antifibrinolytic agents to delay or slow fibrinolysis, which leads to destruction of the gel. These include, epsilon-aminocaproic acid, C1-esterase inhibitor and aprotinin, of which aprotinin is most common [14–16]. In addition to varied release kinetics involving the gel, fibrin glue is an attractive drug delivery system due to the interactions it can have with endogenous factors.
Mechanical Properties of Surgical Glues Used in Aortic Root Replacement
2009, Annals of Thoracic SurgeryRecent clinical and investigational applications of fibrin sealant in selected surgical specialties
2006, Journal of the American College of Surgeons
- ☆
Supported in part by a gift from Johnson & Johnson Patient Care, Inc. and by NIH Grant HL-45786.